Objective：To study the clinical effect of Monosialotetrahexosylganglioside in treatment of the neonatal hypoxic ischemic encephalopathy(HIE).

Methods：Totally 108 HIE neonates were randomly divided into control group(54 cases) and treatment group(54 cases). The control group was given the following routine treatment: lowering the intracranial pressure, keeping the water and dielectric balance, control convulsion, and maintaining good ventilation. The observation group was given the same treatment; in addition, monosialotetrahexosylganglioside was given by intravenous dripping, once a day, for 10 days continuously. Observe the therapeutic effect of the two groups as well as the NBNA score and the recovery of clinical signs(sucking, primary reflex, muscle tone and consciousness).

Results：The total effective rate of the observation group was 92.6%(50/54), significantly higher than that of the control group(75.9%,41/54)(P<0.05). The recovery time of observation group was significantly shorter than the control group(P<0.05). NBNA score was significantly higher in the observation group than in the control group after treatment.

Conclusion：For HIE neonates, monosialotetrahexosylganglioside can efficiently promote the recovery of neurological function, shorten the clinical treatment time, and improve the clinical treatment effect, which is worthy of promotion and application.